Processa Pharmaceuticals, Inc. Announces Closing of $6.25 Million Registered Direct Offering, Which Included Retail Investors and Insiders, Priced at the Market Under Nasdaq Rules
15 févr. 2023 08h30 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a diversified clinical-stage company developing next generation...
Processa Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
10 févr. 2023 08h00 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, MD., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a diversified clinical-stage company developing next generation...
Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial
14 déc. 2022 08h30 HE
|
Processa Pharmaceuticals, Inc.
A 0.5 mg daily dose of PCS12852 administered over 28 days in gastroparesis patients successfully improved gastroparesis symptoms in a clinically meaningful way as defined by greater than a 0.5...
IMUNON Announces Strategic Investment in Transomic Technologies
17 nov. 2022 08h30 HE
|
Imunon, Inc.
Investment of $375,000 with Senior Convertible Notes and Warrants; Strengthens Development Capabilities for IMUNON’s PLACCINE DNA Vaccine Platform IMUNON’s Executive Chairman to join Transomic’s...
Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update
08 nov. 2022 16h00 HE
|
Processa Pharmaceuticals, Inc.
PCS12852 successfully demonstrates a positive effect on the gastric emptying rate, clearing the path for a Phase 2B trial in 2023.Next Generation Capecitabine (a combination of PCS6422 and...
Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial
01 nov. 2022 08h30 HE
|
Processa Pharmaceuticals, Inc.
Next Generation Capecitabine (NGC) Dosage Regimens Have Been Identified In The Ongoing Phase 1B Trial With Potentially Better Safety And Efficacy Profiles Than Existing Chemotherapy These NGC...
Celsion Corporation Highlights Progress in its DNA-based Vaccine Program
01 sept. 2022 08h30 HE
|
Celsion Corporation
PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model LAWRENCEVILLE, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company...
Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
19 juil. 2022 08h35 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced...
Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer
19 juil. 2022 08h30 HE
|
Celsion Corporation
Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on...
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
21 juin 2022 08h30 HE
|
Celsion Corporation
Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit Full Enrollment Expected by Third Quarter of 2022 LAWRENCEVILLE, N.J., June 21, 2022 (GLOBE NEWSWIRE) --...